Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (March 2018)
17 slides from Vivani Medical's investor presentation, Mar 7, 2018
Slide 1: Enriching the Lives of the Blind
NASDAQ: EYES Enriching the Lives of the Blind March 2018 NASDAQ: EYES
Slide 2: Forward Looking Statements
NASDAQ: EYES Forward Looking Statements 2 This press release contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “sa
Slide 3: Second Sight Medical Products, Inc.
NASDAQ: EYES Second Sight Medical Products, Inc. • We are a developer, manufacturer and marketer of implantable visual prosthetics • We have created a “Bionic Eye” called the Argus® II that allows blind patients to see 1 • The Argus II is the first & only FDA - approved retinal prosthesis available
Slide 4: What We Offer Blind Individuals?
NASDAQ: EYES What We Offer Blind Individuals? • The Argus II system enables useful vision for patients that are completely blind today 1 o Retinal degenerations, such as retinitis pigmentosa (RP ) o Working on expanding addressable market with Orion I to treat nearly all blind individuals (e.g. glau
Slide 5: Large Targeted Patient Population of 8+ Million
NASDAQ: EYES Large Targeted Patient Population of 8+ Million 5 Total Targeted Patient Population: ~8.2M Age - Related Macular Degeneration (AMD) AMD causes loss of central vision and progresses to blindness Other Forms of Untreatable Blindness Eye trauma, optic nerve disease, glaucoma, diabetic reti
Slide 6: ARGUS II Technology
NASDAQ: EYES ARGUS II Technology A patient’s functional vision is restored via bypassing the damaged part of the retina to send visual signals to the healthy retinal cells 6 Miniature video camera in a patient’s glasses captures images and converts them to electronic pulses Electronic pulses bypass
Slide 7: Orion Technology – The Next Generation
NASDAQ: EYES Orion Technology – The Next Generation Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to send visual signals directly to the brain 7 2 1 These pulses are sent to the video processing unit (VPU) and implant on the surface of th
Slide 8: Progress towards Commercializing Orion
NASDAQ: EYES Progress towards Commercializing Orion 8 • In 2016, Second Sight & UCLA implanted a wireless multichannel neurostimulation system on the visual cortex of a patient o Patient was able to perceive and localize individual phosphenes (or spots of light) with no significant adverse side effe
Slide 9: Established Technology Leadership
NASDAQ: EYES Established Technology Leadership 9 • 400+ patents issued • 80+ patents pending Pioneering Technology Groundbreaking Research Recognized Leadership • 75+ scientific publications • 6 clinical & post - approval studies • Demonstrated benefit of 10+ years post - implant • Numerous innovati
Slide 10: Argus II: An Effective Treatment for Blindness
NASDAQ: EYES Argus II: An Effective Treatment for Blindness 10 Retinal Prosthesis Competitors CE Mark Widely Reimbursed in Europe FDA Approved Reimbursed in USA Second Sight, Argus®II ✔ ✔ ✔ ✔ Retina Implant (Germany) ✔ ✗ ✗ ✗ Pixium Vision (France) ✔ ** ✗ ✗ ✗ Nidek Co., Ltd. (Japan) ✗ ✗ ✗ ✗ Bionic Vi
Slide 11: Cumulative Commercial Implants
NASDAQ: EYES Cumulative Commercial Implants 11 3 6 9 11 18 22 26 31 40 46 49 54 69 88 108 123 144 154 165 179 186 200 219 231 260 - plus 0 50 100 150 200 250 300 2012 2013 2014 2015 2016 2017
Slide 12: Commercial Growth Strategy: Expanding Reimbursement Coverage
NASDAQ: EYES Commercial Growth Strategy: Expanding Reimbursement Coverage 12 • 5 of 7 MACs covering 31 states with positive coverage decisions for Argus II • $122.5k CMS outpatient reimbursement rate for device and surgical procedure in 2018 • Coverage in 2H 2018 in England under “Commissioning thro
Slide 13: Commercial Growth Strategy: Strengthening Centers of Excellence
NASDAQ: EYES Commercial Growth Strategy: Strengthening Centers of Excellence • Full - time vision rehabilitation team for each patient • Individual patient assessment & training program • Local programming & fittings • Full reimbursement for all device & procedure costs of $122.5K in 2018. • CPT cod
Slide 14: Commercial Growth Strategy: Argus II Technology & Market Expansion
NASDAQ: EYES Commercial Growth Strategy: Argus II Technology & Market Expansion 14 • Proprietary durable implanted array + continuous improvement in our externals Argus II platform: o Benefit current patients using the Argus II technology with ongoing enhancements to our VPU, software, camera & exte
Slide 15: Select Financials
NASDAQ: EYES Select Financials 15 1) Non - GAAP adjusted net loss excludes non - cash expenses including stock - based compensation and reserve for excess inventory. (USD $ in Thousands) 2017 FY 2016 Implants 75 (30 implants in Q4) 42 (7 implants in Q4) Revenue $7,964 $3,985 Gross Profit (Loss) 2,84
Slide 16: Second Sight Key Takeaways
NASDAQ: EYES Second Sight Key Takeaways 16 Technology Leadership • Approved for sale in the US, EU and other markets globally • Robust IP portfolio with 500+ patents issued and pending; Over $200M invested to date • Significant first mover advantage with 5+ year lead over any other therapeutic optio
Slide 17: Contacts
NASDAQ: EYES Contacts Retail Investor Relations Greg Falesnik Managing Director MZ North America Direct: 949 - 385 - 6449 Greg.Falesnik@mzgroup.us 17 Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818 - 833 - 5000 www.secondsight.com Institutional Invest
Second Sight Medical Products — Investor Presentation (March 2018) on 6ix